Contec Bio: Notice of approval for clinical drug trial of the cell-free adsorbed DTaP (component) combined vaccine (for adults, adolescents, and children)

Kangtai Biological announces that the fully owned subsidiary Beijing Minhai Biotechnology Co., Ltd.'s developed acellular pertussis (component) combined vaccine (for adults, adolescents, and children) has received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration today.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin